DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Imatinib Mesylate in Treating Patients With Recurrent Meningioma

Phase 2

Completed

Conditions: Adult Meningioma
Adult Meningeal Hemangiopericytoma
Adult Grade II Meningioma
Adult Grade I Meningioma
Adult Grade III Meningioma
Recurrent Adult Brain Tumor

Interventions: Drug: imatinib mesylate
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2017-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT00045734

Locations: 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
National Cancer Institute Neuro-Oncology Branch, Bethesda, Maryland, United States

and more 4 locations

Bortezomib in Treating Patients With Lymphoproliferative Disorders

Phase 2

Completed

Conditions: Recurrent Mantle Cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 1 Follicular Lymphoma

Interventions: Drug: bortezomib

First Posted Date: 2003-01-27

Last Posted Date: 2015-12-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 103

Registration Number: NCT00023764

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate

Not Applicable

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Neurotoxicity
Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT00018967

Locations: 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
Stanford Comprehensive Cancer Center - Stanford, Stanford, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States

and more 100 locations

UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00045500

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
Frederick Cancer Research and Development Center, Frederick, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States

Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors
Childhood Germ Cell Tumor
Neuroblastoma
Unspecified Childhood Solid Tumor, Protocol Specific
Extragonadal Germ Cell Tumor
Sarcoma
Kidney Cancer
Liver Cancer
Ovarian Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020150

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Metastatic Cancer
Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020007

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States

Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Rectum
Recurrent Rectal Cancer
Stage IV Rectal Cancer
Adenocarcinoma of the Colon
Stage IV Colon Cancer
Recurrent Colon Cancer

Interventions: Drug: erlotinib hydrochloride
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00032110

Locations: 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada

Bortezomib in Treating Children With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Drug: bortezomib
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00021216

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Primary Peritoneal Cavity Cancer
Ovarian Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00039585

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States

Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Phase 2

Completed

Conditions: Stage IV Skin Melanoma
Recurrent Melanoma

Interventions: Biological: Recombinant Interferon Alfa
Biological: Bevacizumab

First Posted Date: 2003-01-27

Last Posted Date: 2016-03-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 57

Registration Number: NCT00026221

Locations: 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy